Letrozole versus clomiphene is an important comparison in ovulation induction for PCOS. Evidence favoring letrozole in that population does not mean clomiphene has disappeared or that one medicine is best for every infertility diagnosis. The treatment goal, population and outcome matter.
For decades, the first chapter of fertility treatment has remained identical for millions: a single pill called Clomiphene. It was the de facto starting point, the “gold standard” that held its ground for decades. Today, however, that foundation is shifting.
For anovulatory infertility in PCOS, evidence supports letrozole as a first-line option in appropriate patients. This is not a universal phase-out of clomiphene.
Compare the same population and outcome
- Population: The comparative trial discussed here enrolled women with PCOS. It does not establish the preferred medicine for all causes of infertility.
- Risks and monitoring: Multiple pregnancy and other treatment risks belong in counseling for either pathway. A drug label is not a guarantee of a single pregnancy.
- The endometrium: Clomiphene can have anti-estrogenic effects. A lining measurement alone cannot establish the reason for treatment failure or prove a live-birth advantage.
A multicenter randomized trial of 750 women with PCOS found higher live-birth and ovulation rates with letrozole than clomiphene over up to five cycles. The finding should not be generalized to every infertility diagnosis.
The comparison is a clinical evidence question rather than proof that reproductive medicine has abandoned egg numbers for an entirely new philosophy.
More than a medication label
Response, adverse effects and the treatment plan matter. Endometrial thickness may contribute information but does not alone certify receptivity.
Clomiphene remains an option in relevant settings. Patients need an explanation of why a particular medicine fits their diagnosis rather than a declaration that an era has ended.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and various public data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.
The primary trial and its limits
Legro and colleagues reported a randomized trial of 750 women with PCOS in the New England Journal of Medicine (2014). DOI: 10.1056/NEJMoa1313517. Participants received treatment for up to five cycles. The population and treatment setting limit generalization to other diagnoses. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome.
Related reading
Thin Endometrium and IVF: Is the 7 mm Rule Telling the Whole Story?